Literature DB >> 33652031

Glecaprevir/pibrentasvir + sofosbuvir + ribavirin offers high cure rate for hepatitis C virus retreatment in real-world settings.

Michelle T Martin1, Sonalie Patel2, Laura Kulik2, Christine Chan3.   

Abstract

Entities:  

Keywords:  direct-acting antivirals; glecaprevir/pibrentasvir; hepatitis C virus; retreatment; ribavirin; salvage therapy; sofosbuvir

Year:  2021        PMID： 33652031     DOI： 10.1016/j.jhep.2021.02.024

Source DB:  PubMed          Journal:  J Hepatol        ISSN： 0168-8278            Impact factor:   25.083


× No keyword cloud information.
  3 in total

Review 1.  Breakthroughs in hepatitis C research: from discovery to cure.

Authors:  Michael P Manns; Benjamin Maasoumy
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2022-05-20       Impact factor: 73.082

2.  National Brazilian survey on the outcomes of hepatitis c retreatment in patients non-responders to direct antiviral agents.

Authors:  Maria Lúcia Gomes Ferraz; Leonora de Zorzi Piccoli; Rosamar Rezende; Luiz Augusto Borba; Alcindo Pissaia Junior; Hugo Cheinquer; Giovanni Faria Silva; Paulo Roberto Abrão Ferreira; Cristiane Alves Villela-Nogueira; Daniel Ferraz Mazo; Fernanda Fernandes Souza; Liana Codes; Claudia Alexandra Pontes Ivantes; Geisa Perez Medina Gomide; Gustavo Henrique Santos Pereira; Mário Guimarães Pessôa; Alex Vianey Callado França; Arlene Dos Santos Pinto; Rosângela Teixeira; Paulo Lisboa Bittencourt
Journal:  Braz J Infect Dis       Date:  2022-07-26       Impact factor: 3.257

3.  Retreatment of Chronic Hepatitis C Infection: Real-World Regimens and Outcomes From National Treatment Programs in Three Low- and Middle-Income Countries.

Authors:  Caroline E Boeke; Lindsey Hiebert; Imam Waked; Tengiz Tsertsvadze; Lali Sharvadze; Maia Butsashvili; Mamuka Zakalashvili; Win Naing; Neil Gupta; Fredrick Kateera; Craig McClure; John W Ward; Christian B Ramers
Journal:  Clin Infect Dis       Date:  2022-02-11       Impact factor: 9.079
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.